North America Whole Exome Sequencing Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF NORTH AMERICA WHOLE EXOME SEQUENCING (WES) MARKET 13
1.4 CURRENCY AND PRICING 15
1.5 LIMITATIONS 15
1.6 MARKETS COVERED 16
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 20
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.6 MULTIVARIATE MODELLING 24
2.7 MARKET APPLICATION COVERAGE GRID 25
2.8 PRODUCT TYPE LIFELINE CURVE 26
2.9 Cognate Lifesciences MARKET POSITION GRID 27
2.10 SECONDARY SOURCES 28
2.11 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHT 32
4.1 PORTER’S FIVE FORCES 33
4.2 PESTEL ANALYSIS 34
4.3 INDUSTRIAL INSIGHTS: 35
4.4 CONCLUSION 36
5 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS 37
6 MARKET OVERVIEW 39
6.1 DRIVERS 41
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 41
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 41
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 41
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 42 
6.2 RESTRAINTS 43
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 43
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 43
6.3 OPPORTUNITIES 44
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 44
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 44
6.4 CHALLENGES 45
6.4.1 LACK OF SKILLED PROFESSIONALS 45
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 45
7 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 46
7.1 OVERVIEW 47
7.2 SECOND-GENERATION SEQUENCING 50
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 51
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 51
7.3 THIRD-GENERATION SEQUENCING 52
8 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 53
8.1 OVERVIEW 54
8.2 SYSTEMS 57
8.2.1 HISEQ SERIES 57
8.2.1.1 HISEQ 2500 58
8.2.1.2 HISEQ 1500 58
8.2.2 MISEQ SERIES 58
8.2.3 ION TORRENT PLATFORMS 59
8.2.3.1 ION PROTON 59
8.2.3.2 ION PGM 59
8.2.4 OTHERS 59
8.3 KITS 59
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 60
8.3.2 LIBRARY PREPARATION KITS 60
8.3.3 TARGET ENRICHMENT KITS 61
8.3.4 OTHERS 61
8.4 SERVICES 61
8.4.1 SEQUENCING SERVICES 62
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 62
8.4.3 OTHERS 62 
9 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 63
9.1 OVERVIEW 64
9.2 DRUG DISCOVERY AND DEVELOPMENT 67
9.3 AGRICULTURE & ANIMAL RESEARCH 67
9.4 DIAGNOSTICS 68
9.5 PERSONALIZED MEDICINE 68
9.6 OTHERS 69
10 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY END USER 70
10.1 OVERVIEW 71
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 74
10.3 ACADEMIC & RESEARCH INSTITUTES 75
10.4 HOSPITALS AND CLINICS 75
10.5 CLINICAL LABORATORIES 75
10.6 OTHERS 76
11 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 77
11.1 OVERVIEW 78
11.2 DIRECT TRADE 81
11.3 RETAIL SALES 81
11.4 OTHERS 82
12 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET, BY REGION 83
12.1 NORTH AMERICA 84
12.1.1 U.S. 88
12.1.2 CANADA 91
12.1.3 MEXICO 94
13 NORTH AMERICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 97
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 97
14 COMPANY PROFILE 98
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 98
14.1.1 COMPANY SNAPSHOT 98
14.1.2 PRODUCT PORTFOLIO 98
14.1.3 RECENT DEVELOPMENTS 99 
14.2 MERCK KGAA 100
14.2.1 COMPANY SNAPSHOT 100
14.2.2 REVENUE ANALYSIS 100
14.2.3 PRODUCT PORTFOLIO 101
14.2.4 RECENT DEVELOPMENTS 101
14.3 EXODX (A PART OF BIO-TECHNE) 102
14.3.1 COMPANY SNAPSHOT 102
14.3.2 PRODUCT PORTFOLIO 102
14.3.3 RECENT DEVELOPMENTS 102
14.4 THERMO FISHER SCIENTIFIC INC. 103
14.4.1 COMPANY SNAPSHOT 103
14.4.2 REVENUE ANALYSIS 103
14.4.3 PRODUCT PORTFOLIO 104
14.4.4 RECENT DEVELOPMENTS 104
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 105
14.5.1 COMPANY SNAPSHOT 105
14.5.2 PRODUCT PORTFOLIO 105
14.5.3 RECENT DEVELOPMENTS 106
14.6 AZENTA US, INC. 107
14.6.1 COMPANY SNAPSHOT 107
14.6.2 PRODUCT PORTFOLIO 107
14.6.3 RECENT DEVELOPMENTS 108
14.7 BECKMAN COULTER, INC 109
14.7.1 COMPANY SNAPSHOT 109
14.7.2 PRODUCT PORTFOLIO 109
14.7.3 RECENT DEVELOPMENTS 110
14.8 CD GENOMICS 111
14.8.1 COMPANY SNAPSHOT 111
14.8.2 PRODUCT PORTFOLIO 111
14.8.3 RECENT DEVELOPMENTS 111
14.9 EUROFINS SCIENTIFIC 112
14.9.1 COMPANY SNAPSHOT 112
14.9.2 REVENUE ANALYSIS 112
14.9.3 PRODUCT PORTFOLIO 113
14.9.4 RECENT DEVELOPMENTS 113
14.10 GENEDX, LLC 114
14.10.1 COMPANY SNAPSHOT 114
14.10.2 PRODUCT PORTFOLIO 114
14.10.3 RECENT DEVELOPMENTS 115 
14.11 GENEFIRST LIMITED. 116
14.11.1 COMPANY SNAPSHOT 116
14.11.2 PRODUCT PORTFOLIO 116
14.11.3 RECENT DEVELOPMENTS 116
14.12 ILLUMINA, INC 117
14.12.1 COMPANY SNAPSHOT 117
14.12.2 REVENUE ANALYSIS 117
14.12.3 PRODUCT PORTFOLIO 118
14.12.4 RECENT DEVELOPMENTS 118
14.13 INTEGRATED DNA TECHNOLOGIES, INC. 119
14.13.1 COMPANY SNAPSHOT 119
14.13.2 PRODUCT PORTFOLIO 119
14.13.3 RECENT DEVELOPMENTS 120
14.14 MERIDIAN BIOSCIENCE, INC. 121
14.14.1 COMPANY SNAPSHOT 121
14.14.2 REVENUE ANALYSIS 121
14.14.3 PRODUCT PORTFOLIO 122
14.14.4 RECENT DEVELOPMENTS 122
14.15 PSOMAGEN 123
14.15.1 COMPANY SNAPSHOT 123
14.15.2 REVENUE ANALYSIS 123
14.15.3 PRODUCT PORTFOLIO 124
14.15.4 RECENT DEVELOPMENTS 124
14.16 QIAGEN 125
14.16.1 COMPANY SNAPSHOT 125
14.16.2 REVENUE ANALYSIS 125
14.16.3 PRODUCT PORTFOLIO 126
14.16.4 RECENT DEVELOPMENTS 126
14.17 SOPHIA GENETICS 127
14.17.1 COMPANY SNAPSHOT 127
14.17.2 REVENUE ANALYSIS 127
14.17.3 PRODUCT PORTFOLIO 128
14.17.4 RECENT DEVELOPMENTS 128
14.18 TWIST BIOSCIENCE 129
14.18.1 COMPANY SNAPSHOT 129
14.18.2 REVENUE ANALYSIS 129
14.18.3 PRODUCT PORTFOLIO 130
14.18.4 RECENT DEVELOPMENTS 130 
15 QUESTIONNAIRE 131
16 RELATED REPORTS 134